328007
ERK抑制剂II，FR180204
ERK Inhibitor II, FR 180204, CAS 865362-74-9, is a cell-permeable, potent, ATP-competitive inhibitor of ERK1 and ERK2 (IC₅₀ = 510 nM and 330 nM; Ki = 310 nM and 140 nM, respectively).
别名:
ERK抑制剂II，FR180204, 5-(2-苯基-吡唑并[1,5-a]吡啶-3-基)-1H-吡唑并[3,4-c]哒嗪-3-基胺
登录查看公司和协议定价
所有图片(1)
About This Item
推荐产品
质量水平
方案
≥98% (HPLC)
表单
solid
制造商/商品名称
Calbiochem®
储存条件
OK to freeze
protect from light
颜色
yellow
溶解性
DMSO: 10 mg/mL
运输
ambient
储存温度
2-8°C
InChI
1S/C18H13N7/c19-17-12-10-13(20-22-18(12)23-21-17)15-14-8-4-5-9-25(14)24-16(15)11-6-2-1-3-7-11/h1-10H,(H3,19,21,22,23)
InChI key
XVECMUKVOMUNLE-UHFFFAOYSA-N
一般描述
一种细胞可渗透性吡唑并哒嗪胺，可作为ERK1和ERK2的有效，ATP竞争性抑制剂（IC50分别为510 nM和330 nM；Ki分别为310 nM和140 nM）。选择性比p38高约20倍α（IC50 = 10 µM），对IKKα、MEK1、MKK4、PDGFRα、PKCα、Src和Syk几乎没有活性，即使在浓度高达30 µM时也是如此。在Mv1Lu上皮细胞中显示出抑制TGFβ−-诱导的AP-1活化的作用（IC50为3.1 µM）。也可用ERK抑制剂II，阴性对照（目录编号328008）。 也可以10 mM的DMSO溶液（目录号328010）提供。
一种细胞可渗透性吡唑并哒嗪胺，可作为ERK1和ERK2的有效，ATP竞争性抑制剂（IC50分别为510 nM和330 nM；Ki分别为310 nM和140 nM）。选择性比p38高约20倍α（IC50 = 10 µM），对IKKα、MEK1、MKK4、PDGFRα、PKCα、Src和Syk几乎没有活性，即使在浓度高达30 µM时也是如此。在Mv1Lu上皮细胞中显示出抑制TGFβ−-诱导的AP-1活化的作用（IC50为3.1 µM）。也可用ERK抑制剂II，阴性对照（目录编号328008）。也可提供InSolution形式（目录号328010）。
生化/生理作用
主要靶标
ERK1和ERK2
ERK1和ERK2
产物与ATP竞争。
可逆：否
细胞可渗透性：是
靶标IC50：510 nm和330 nm
靶标Ki：310 nM和140 nM，分别针对ERK1和ERK2
包装
用惰性气体包装
警告
毒性：标准处理（A）
重悬
复溶后，等分并冷冻保存（-20°C）。储备溶液在-20°C下可稳定保存至多6个月。
其他说明
Ohori, M., et al. 2005.Biochem.Biophys.Res. Commun.336, 357.
法律信息
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
储存分类代码
11 - Combustible Solids
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
Jiawen Yong et al.
International journal of molecular sciences, 23(15) (2022-08-13)
Ciliary neurotrophic factor (CNTF) was identified as a survival factor in various types of peripheral and central neurons, glia and non-neural cells. At present, there is no available data on the expression and localization of CNTF-receptors in cementoblasts as well
Jiawen Yong et al.
Journal of cellular and molecular medicine, 25(20), 9710-9723 (2021-09-16)
Hypoxia-induced apoptosis of cementoblasts (OCCM-30) may be harmful to orthodontic treatment. Hypoxia-inducible factor 1-alpha (HIF-1α) mediates the biological effects during hypoxia. Little is known about the survival mechanism capable to counteract cementoblast apoptosis. We aimed to investigate the potential roles
Zahra S Thirouin et al.
The Journal of biological chemistry, 298(5), 101840-101840 (2022-03-22)
Posttranslational addition of a small ubiquitin-like modifier (SUMO) moiety (SUMOylation) has been implicated in pathologies such as brain ischemia, diabetic peripheral neuropathy, and neurodegeneration. However, nuclear enrichment of SUMO pathway proteins has made it difficult to ascertain how ion channels
Yen-You Lin et al.
Journal of cellular physiology, 236(10), 6988-7000 (2021-03-28)
The pro-inflammatory cytokine interleukin 1 beta (IL-1β) plays a critical role in osteoarthritis (OA) disease pathogenesis. MicroRNA (miRNA) activity is related to inflammation in OA and some miRNAs specifically regulate IL-mediated degradation of cartilage type II collagen. Previous studies have
G Ruiz-Heiland et al.
Clinical oral investigations, 25(4), 1933-1944 (2020-08-21)
Juvenile obesity is a complex clinical condition that is present more and more frequently in the daily orthodontic practice. Over-weighted patients have an impaired bone metabolism, due in part to their increased levels of circulating adipokines. Particularly, leptin has been
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门